Table 2.

In vitro activity of ceftolozane/tazobactam and comparators against 386 and 70 Enterobacterales isolates from Kuwait and Oman, respectively

Antimicrobial agent	Antimicrobial susceptibilitya
	E. coli: Kuwait (n = 164), Oman (n = 29)						K. pneumoniae: Kuwait (n = 133), Oman (n = 26)						other Enterobacterales: Kuwait (n = 89), Oman (n = 15)
	%			mg/L			%			mg/L			%			mg/L
	S	I	R	MIC50	MIC90	range	S	I	R	MIC50	MIC90	range	S	I	R	MIC50	MIC90	range
Ceftolozane/tazobactam
Kuwait	95.7	0.6	3.7	0.25	1	≤0.06 to >32	85.7	0.8	13.5	0.5	32	0.12 to >32	88.8	2.3	9	0.5	4	0.12 to 32
Oman	93.1	0	6.9	0.25	2	0.12 to >32	88.5	3.9	7.7	0.5	4	0.25 to >32	86.7	6.7	6.7	0.5	4	0.25 to 16
Amikacin
Kuwait	100	0	0	≤4	8	≤4 to 16	95.5	0	4.5	≤4	8	≤4 to >32	98.9	1.1	0	≤4	8	≤4 to >32
Oman	93.1	3.5	3.5	≤4	8	≤4 to >32	92.3	0	7.7	≤4	≤4	≤4 to >32	100	0	0	≤4	16	≤4 to 16
Aztreonam
Kuwait	56.1	6.7	37.2	4	>16	≤1 to >16	53.4	3	43.6	2	>16	≤1 to >16	71.9	2.3	25.8	≤1	>16	≤1 to >16
Oman	55.2	3.5	41.4	2	>16	≤1 to >16	53.9	0	46.2	≤1	>16	≤1 to >16	73.3	6.7	20	≤1	>16	≤1 to >16
Cefepime
Kuwait	58.5	11	30.5	≤1	>32	≤1 to >32	55.6	9	35.3	2	>32	≤1 to >32	74.2	5.6	20.2	≤1	>32	≤1 to >32
Oman	55.2	6.9	37.9	≤1	>32	≤1 to >32	53.9	7.7	38.5	≤1	>32	≤1 to >32	73.3	13.3	13.3	≤1	16	≤1 to >32
Cefotaxime
Kuwait	50	0.6	49.4	≤1	>32	≤1 to >32	48.9	0.8	50.4	4	>32	≤1 to >32	61.8	3.4	34.8	≤1	>32	≤1 to >32
Oman	44.8	10.3	44.8	2	>32	≤1 to >32	53.9	0	46.2	≤1	>32	≤1 to >32	73.3	0	26.7	≤1	>32	≤1 to >32
Cefoxitin
Kuwait	70.7	15.2	14	8	>16	≤2 to >16	71.4	9	19.6	4	>16	≤2 to >16	60.7	0	39.3	4	>16	≤2 to >16
Oman	79.3	6.9	13.8	8	>16	4 to >16	88.5	3.9	7.7	4	16	≤2 to >16	33.3	6.7	60	>16	>16	≤2 to >16
Ceftazidime
Kuwait	60.4	12.2	27.4	2	32	≤1 to >32	54.1	5.3	40.6	2	>32	≤1 to >32	71.9	5.6	22.5	≤1	32	≤1 to >32
Oman	62.1	6.9	31	≤1	>32	≤1 to >32	53.9	3.9	42.3	≤1	>32	≤1 to >32	73.3	6.7	20	≤1	>32	≤1 to >32
Ceftriaxone
Kuwait	48.8	1.8	49.4	2	>32	≤1 to >32	49.6	2.3	48.1	2	>32	≤1 to >32	62.9	2.3	34.8	≤1	>32	≤1 to >32
Oman	55.2	0	44.8	≤1	>32	≤1 to >32	50	0	50	≤1	>32	≤1 to >32	73.3	0	26.7	≤1	>32	≤1 to >32
Ciprofloxacin
Kuwait	41.5	1.2	57.3	>2	>2	≤0.25 to >2	60.2	9	30.8	0.5	>2	≤0.25 to >2	46.1	10.1	43.8	2	>2	≤0.25 to >2
Oman	65.5	3.5	31	0.5	>2	≤0.25 to >2	65.4	11.5	23.1	≤0.25	>2	≤0.25 to >2	80	0	20	≤0.25	>2	≤0.25 to >2
Colistin
Kuwait	100	—	0	≤1	≤1	≤1 to 2	94	—	6	≤1	≤1	≤1 to 4	41.6	—	58.4	>4	>4	≤1 to 4
Oman	96.6	—	3.5	≤1	≤1	≤1 to 4	100	—	0	≤1	≤1	≤1 to 2	40	—	60	>4	>4	≤1 to 4
Ertapenem
Kuwait	97.6	1.2	1.2	≤0.06	≤0.06	≤0.06 to 4	86.5	0.8	12.8	≤0.06	2	≤0.06 to >4	92.1	2.3	5.6	≤0.06	0.5	≤0.06 to >4
Oman	100	0	0	≤0.06	≤0.06	≤0.06 to 0.25	96.2	0	3.9	≤0.06	0.12	≤0.06 to >4	93.3	6.7	0	≤0.06	≤0.06	≤0.06 to 1
Imipenem
Kuwait	100	0	0	≤0.5	≤0.5	≤0.5 to 1	94	1.5	4.5	≤0.5	1	<0.5 to >32	68.5	30.3	1.1	1	2	≤0.5 to 4
Oman	100	0	0	≤0.5	≤0.5	≤0.5 to <0.5	96.2	0	3.9	≤0.5	≤0.5	≤0.5 to 4	86.7	6.7	6.7	≤0.5	2	≤0.5 to 4
Levofloxacin
Kuwait	42.1	3.1	54.9	>4	>4	≤1 to >4	74.4	4.5	21.1	≤1	>4	≤1 to >4	60.7	11.2	28.1	2	>4	≤1 to >4
Oman	65.5	3.5	31	≤1	>4	≤1 to >4	80.8	7.1	11.5	≤1	>4	≤1 to >4	80	6.7	13.3	≤1	>4	≤1 to >4
Meropenem
Kuwait	100	0	0	≤0.12	≤0.12	≤0.12 to 0.5	94	0.8	5.3	<0.12	0.5	≤0.12 to >16	97.8	1.1	1.1	≤0.12	≤0.12	≤0.12 to 16
Oman	100	0	0	≤0.12	≤0.12	≤0.12 to ≤0.12	96.2	0	3.9	≤0.12	≤0.12	≤0.12 to >16	100	0	0	≤0.12	≤0.12	≤0.12 to ≤0.12
Piperacillin/tazobactam
Kuwait	90.9	4.3	4.9	≤2	16	≤2 to >64	75.9	8.3	15.8	4	>64	≤2 to >64	80.9	10.1	9	≤2	64	≤2 to >64
Oman	86.2	6.9	6.9	≤2	64	≤2 to >64	76.9	3.9	19.2	4	>64	≤2 to >64	93.3	0	6.7	≤2	8	≤2 to >64

^aStratified by country.